Gubra

610

DKK

-13.84 %

GUBRA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

26 following

-13.84%

+6.64%

+20.55%

+39.91%

+388%

+395.53%

-

-

+454.55%

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They mainly conduct research and development in the field of metabolic and fibrotic diseases. The company's product portfolio includes several brands and pharmaceuticals, and operations are conducted on a global level, with the largest presence in North America and the Nordics. The head office is located in Hørsholm, Denmark.

Market cap

9.97B DKK

Turnover

92.17M DKK

Revenue

205.01M

EBIT %

-23.25 %

P/E

-

Dividend yield-%

-

Coverage

Latest research

Latest analysis report

Released: 2024-09-09

Financial calendar

28/2

2025

Annual report '24

ShowingAll content types

Regulatory press release11/13/2024, 5:36 PM

Gubra announces positive GUBamy Phase 1 SAD data (correction)

Regulatory press release11/13/2024, 4:41 PM

Gubra announces positive GUBamy Phase 1 SAD data

Gubra: Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Analyst Comment11/8/2024, 9:46 AM by

Gubra: Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Wrap up from Q3 event with CEO Henrik Blou and CFO Kristian Borbos

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Gubra – Presentation of Q3 2024

Webcast11/7/2024, 11:00 AM by

Gubra – Presentation of Q3 2024

Meet and ask questions to Gubra’s management – CEO Henrik Blou and CFO Kristian Borbos on 7 November at 12.00 AM when they present the Q3 report 2024. Focus will be on Q3 report and the underlying growth in the CRO business area. Besides that, we expect an update on potential triggers in the D&P pipeline.

Gubra: Another strong quarter in CRO and pipeline update

Analyst Comment11/7/2024, 8:04 AM by

Gubra: Another strong quarter in CRO and pipeline update

Today, Gubra reported its Q3 2024 results. The company saw another strong quarter in the CRO business, driven by obesity service which is a major topic for the biotech and pharma industry.Read more here.

Regulatory press release11/7/2024, 6:30 AM

Trading statement Q3-2024: Another strong quarter

Gubra: Shares drop 4% yesterday amid pipeline news, despite the news relating to a smaller part of our pipeline valuation

Analyst Comment10/31/2024, 1:04 PM by

Gubra: Shares drop 4% yesterday amid pipeline news, despite the news relating to a smaller part of our pipeline valuation

Boehringer Ingelheim, Gubra's partner in multiple obesity projects, has decided to discontinue the clinical obesity project NYP2.

Regulatory press release10/31/2024, 10:07 AM

Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim

Gubra (One pager): Obesity Market Upgrade Enhances DCF Estimates

Research9/9/2024, 2:02 PM by

Philip Coombes, Claus Thestrup

Gubra (One pager): Obesity Market Upgrade Enhances DCF Estimates

We have revised our DCF-model, guided by the company, to reflect new estimates for the total obesity market in 2030. With the current share price in line with our latest one-pager from June 2024, the model indicates a lower probability og success (PoS) in the base case.

Regulatory press release9/6/2024, 7:42 PM

Major shareholder announcement

Gubra - Presentation of Q2 report 2024

Webcast8/23/2024, 11:00 AM by

Gubra - Presentation of Q2 report 2024

Meet and ask questions to Gubra’s management – CEO Henrik Blou and CFO Kristian Borbos on 23 August at 13.00 when they present the Q2 report 2024.

Regulatory press release8/22/2024, 5:30 AM

Interim report H1 2024: Strong performance across Gubra

Regulatory press release8/21/2024, 3:12 PM

Gubra raises financial outlook for 2024

Regulatory press release7/10/2024, 9:38 PM

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Regulatory press release7/2/2024, 6:25 PM

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra: Share price moves to all-time high as another partner project enters phase 1

Analyst Comment7/2/2024, 6:06 AM by

Henrik Ekman, Claus Thestrup

Gubra: Share price moves to all-time high as another partner project enters phase 1

Gubra’s stock was up 23 percent yesterday as Gubra announced that their partner Boehringer Ingelheim will bring one of its obesity product candidates co-developed by Gubra into phase 1

Regulatory press release7/1/2024, 5:30 AM

Boehringer Ingelheim and Gubra announce start of clinical development of a potential first-in-class, triple agonist, obesity treatment

Regulatory press release6/28/2024, 10:05 AM

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

HCA Capital: Wrap up from 2024 Life Science seminar

Analyst Comment6/6/2024, 9:32 AM by

Henrik Ekman, Claus Thestrup

HCA Capital: Wrap up from 2024 Life Science seminar

At our annual HCA Life Science Seminar on June 4th 2024 Ascelia Pharma, Gubra, BioPorto, Pharma Equity Group and ExpreS2ion Biotechnoligies presented their companies and took questions.

Ascelia Pharma Gubra BioPorto Pharma Equity Group ExpreS2ion Biotech Holding

Regulatory press release6/4/2024, 1:30 PM

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.